Core Viewpoint - Taihe Technology (300801) clarified that its brainwave biofeedback device is not part of the company's main business and is currently not on the market, being in the performance and appearance optimization stage, which does not significantly impact the company's operating performance [1] Summary by Relevant Categories - **Product Development** - The brainwave biofeedback device is still in the optimization phase and has not been launched in the market [1] - **Business Impact** - The project does not have a significant impact on the company's operating performance at this stage [1] - **Investor Communication** - The company encourages investors to pay attention to regular announcements for updates on the project [1]

Group 1 - The core viewpoint of the article is that Taihe Technology's brainwave biofeedback device is currently based on classical algorithms and has not yet adopted deep learning or AI technologies [1] - The technology is still in the internal performance testing and appearance design optimization phase and has not been launched in the market [1]

Core Viewpoint - Taihe Technology (300801) is currently improving the performance and appearance of its brainwave biofeedback device, which has not yet entered mass production and is not accepting orders, indicating a need for caution regarding investment risks [1]. Group 1 - The brainwave biofeedback device developed by Taihe Technology is undergoing continuous improvements [1]. - The device has not yet reached the stage of mass production [1]. - Taihe Technology is currently unable to accept orders for the device [1].

Core Viewpoint - The brain-computer interface (BCI) sector is rapidly transitioning from science fiction to reality, with significant market interest and investment from major financial institutions like Goldman Sachs, Morgan Stanley, and Barclays, leading to a notable surge in stock prices within this sector [1][3]. Group 1: Market Performance - On January 5, 2026, the BCI sector in the A-share market experienced a remarkable increase of 13.7%, with 28 concept stocks reaching their daily limit [1]. - The BCI market is projected to have a potential scale of $15 billion to $85 billion in serious medical applications and $25 billion to $60 billion in consumer medical applications [5]. Group 2: Policy and Technological Advancements - Since 2025, there have been numerous positive developments in the BCI field, including clear policy support, successful corporate financing, and significant clinical breakthroughs [3]. - The Ministry of Industry and Information Technology and six other departments have defined BCI as a future industry in 2024, and the National Healthcare Security Administration established independent pricing for BCI technology in March 2025 [3][5]. Group 3: Key Companies and Investments - Five companies in the BCI sector have received substantial investments from foreign institutions, positioning them as core targets in this field [5]. - Innovation Medical is a pioneer in invasive BCI technology, holding a 40% stake in Hangzhou Boling Brain Machine Technology Co., which has developed an upper limb exoskeleton rehabilitation training system [5]. - Aiheng Medical is integrating BCI with artificial intelligence, focusing on pain management and developing a multimodal ADHD training system [9]. Group 4: Clinical Applications and Innovations - Fudan University Huashan Hospital completed the world's first spinal interface surgery, allowing paraplegic patients to regain standing and walking abilities [5][12]. - The BCI technology is being applied in various fields, including rehabilitation, smart living, and human-computer interaction, showcasing its vast potential [12]. Group 5: Investment Trends - In Q3 2025, foreign capital significantly increased its holdings in key BCI companies, with Goldman Sachs increasing its stake in Innovation Medical to 3.3 million shares [5]. - Companies like Taihe Technology and Sanbo Neuroscience are also attracting foreign investments, indicating a growing interest in the BCI sector [7][9].

Core Viewpoint - The company is currently improving the performance and appearance of its brainwave biofeedback device, which has not yet entered mass production and is not accepting orders [1] Group 1 - The brainwave biofeedback device is under continuous development [1] - The company has not started mass production of the device [1] - Orders for the device are not being accepted at this time [1]

Core Viewpoint - Taihe Technology has developed brainwave biofeedback devices for training and therapy in the human-computer interaction field, indicating a focus on innovative health technology solutions [1] Group 1: Product Development - The company has established an instrument equipment project team dedicated to the development of brainwave biofeedback devices [1] - Two products have been developed: one for personal use to assist meditation through alpha or theta wave feedback, and another for collective training and therapeutic assistance [1] - The design phase of the products is complete, and they are currently undergoing prototype testing and aesthetic optimization [1]

Group 1: Production and Technology - Continuous production at Taihe Technology refers to automated, continuous input and output processes, offering advantages such as safety, lower investment, stable product quality, and reduced labor needs [1] - The annual production capacity of self-produced phosphorus trichloride is 240,000 tons, with significant technical advantages leading to lower production costs for downstream phosphorus-containing products [2] - Current projects for PEEK, PEN, and PPS are in the pilot testing stage, with PEEK samples already being sent out [2] Group 2: Research and Development - Taihe Technology has approximately 150 R&D personnel, excluding analysis, design, and engineering staff, with the lithium sulfide project team composed entirely of internally trained professionals [3] - The brain biofeedback device developed by Taihe Technology provides real-time feedback for meditation, enhancing user experience compared to existing products [2] Group 3: Incentive Mechanism - The incentive mechanism for executives includes performance indicators linked to business operations, with year-end bonuses based on the completion of these indicators [3] - Business personnel's compensation consists of a fixed salary plus year-end bonuses, determined by market development performance [3] Group 4: Future Growth Points - Future profit growth is expected to come from water treatment agents, electronic chemicals, new materials, battery materials (including sodium battery components and solid-state electrolyte raw materials), and ongoing and planned projects [4]